Phase I/Ib study of parsaclisib plus standard immunochemotherapy for newly diagnosed DLBCL

Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, shares insights into a Phase I/Ib trial evaluating parsaclisib plus standard immunochemotherapy in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with high-risk features. Dr Wang highlights the rates of hematological and non-hematological toxicities observed, and the combination showed a high response rate of 98% and a progression-free survival (PFS) of 85% at two years. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.